XSpray Pharma AB Working Capital to Net Assets Ratio
XSpray Pharma AB working capital to net assets ratio. XSpray Pharma AB (XSPRAY) has a Working Capital to Net Assets ratio of 9.5% as of June 2026. Working capital of Skr60.49 Million (current assets of Skr215.11 Million minus current liabilities of Skr154.62 Million) is measured against net assets of Skr637.50 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of XSpray Pharma AB to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of XSpray Pharma AB (2015–2025)
Working capital to net assets ratio of XSpray Pharma AB from 2015 to 2025. This chart shows how XSpray Pharma AB's Working Capital to Net Assets ratio has evolved across 11 annual periods from 2015 to 2025. As of June 2026, the ratio stands at 9.5%, reflecting working capital of Skr60.49 Million against net assets of Skr637.50 Million SEK. See how many days can XSpray Pharma AB fund operations to measure how many days the company can operate on defensive assets alone.
XSpray Pharma AB Working Capital to Net Assets Ratio by Year (2015–2025)
XSpray Pharma AB working capital to net assets ratio by year from 2015 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for XSpray Pharma AB from 2015 to 2025, covering 11 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is XSpray Pharma AB's balance sheet.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 26.7% | Skr161.23 Million | Skr604.65 Million | Skr182.90 Million | Skr21.66 Million | ▲ +12.4 pp |
| 2024 | 14.3% | Skr88.93 Million | Skr623.10 Million | Skr235.07 Million | Skr146.14 Million | ▼ -11.4 pp |
| 2023 | 25.7% | Skr177.91 Million | Skr693.41 Million | Skr217.81 Million | Skr39.90 Million | ▲ +7.1 pp |
| 2022 | 18.6% | Skr103.38 Million | Skr556.02 Million | Skr132.23 Million | Skr28.85 Million | ▼ -24.0 pp |
| 2021 | 42.6% | Skr252.10 Million | Skr591.75 Million | Skr282.06 Million | Skr29.97 Million | ▼ -10.8 pp |
| 2020 | 53.4% | Skr311.20 Million | Skr582.59 Million | Skr331.01 Million | Skr19.82 Million | ▲ +1.6 pp |
| 2019 | 51.8% | Skr193.62 Million | Skr373.71 Million | Skr216.13 Million | Skr22.50 Million | ▼ -19.8 pp |
| 2018 | 71.6% | Skr216.09 Million | Skr301.72 Million | Skr226.86 Million | Skr10.77 Million | ▼ -0.1 pp |
| 2017 | 71.7% | Skr111.59 Million | Skr155.66 Million | Skr117.34 Million | Skr5.75 Million | ▲ +16.0 pp |
| 2016 | 55.7% | Skr25.87 Million | Skr46.47 Million | Skr31.26 Million | Skr5.39 Million | ▼ -30.8 pp |
| 2015 | 86.5% | Skr10.61 Million | Skr12.26 Million | Skr13.29 Million | Skr2.69 Million | — |